At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Botulinum Toxin Type A +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)
In Brief
A Phase 2 clinical trial evaluating Botulinum Toxin Type A, Esophagectomy, and 1 other intervention for Esophageal Carcinoma. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This randomized phase II trial studies how well botulinum toxin type A works in preventing complication after surgery in patients with esophageal cancer. Botulinum toxin type A may cause less complications of nausea and vomiting after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJan 2022
Study CompletionApr 2022
TodayJul 2026
First PostedNov 17, 2016
Enrollment StartDec 30, 2016
Primary CompletionJan 28, 2022
Study CompletionApr 28, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.6 years ago
Interventions
Botulinum Toxin Type Abiological
Given IM
Esophagectomyprocedure
Undergo esophagectomy
Quality-of-Life Assessmentother
Ancillary studies